Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer

Journal of Urology

Volumn 190, Issue 6, 2013, Pages 2271-2277

  Lucarelli, Giuseppe ^a   Rutigliano, Monica ^a   Bettocchi, Carlo ^a   Palazzo, Silvano ^a   Vavallo, Antonio ^a   Galleggiante, Vanessa ^a   Trabucco, Senia ^a   Di Clemente, Daniela ^a   Selvaggi, Francesco Paolo ^a   Battaglia, Michele ^a   Ditonno, Pasquale ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Biological markers; Prostate; Prostate specific antigen; Prostatic neoplasms; SPON2 protein, human

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; SCLEROPROTEIN; SPONDIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY;

EID: 84888640403     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.004     Document Type: Article

References (31)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics 2013. CA Cancer J Clin 2013;63:11.
2. Richie JP, Catalona WJ, Ahmann FR et al: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993;42:365.
3. Carvalhal GF, Smith DS, Mager DE et al: Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 1999;161:835.
4. Thompson IM, Pauler DK, Goodman PJ et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239.
5. Sreekumar A, Poisson LM, Rajendiran TM et al: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910.
6. Lucarelli G, Fanelli M, Larocca AM et al: Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 2012;72:1611.
7. Qian X, Li C, Pang B et al: Spondin-2(SPON2), a more prostate-cancer- specific diagnostic biomarker. PLoS One 2012;7:e37225.
8. Postma R and Schröder FH: Screening for prostate cancer. Eur J Cancer 2005;41:825.
9. Fradet Y: Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 2009;19:243.
10. Mikolajczyk SD, Millar LS, Wang TJ et al: A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000;60:756.
11. Stephan C, Kahrs AM, Cammann H et al: A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009;69:198.
12. Sokoll LJ, Wang Y, Feng Z et al: [-2]Proenzyme prostate specific antigen for prostate cancer detection: A National Cancer Institute Early Detection Research Network validation study. J Urol 2008;180:539.
13. Jentzmik F, Stephan C, Miller K et al: Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12.
14. Sreekumar A, Poisson LM, Rajendiran TM et al: Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours (Eur Urol 2010;58:12-8).
15. Eur Urol 2010;58:e29.
16. Colleselli D, Stenzl A and Schwentner C: Re: Florian Jentzmik, Carsten Stephan, Kurt Miller et al: Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:e51.
17. Wu H, Liu T, Ma C et al: GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem 2011;401:635.
18. Cao DL, Ye DW, Zhu Y et al: Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis 2011;14:166.
19. Struys EA, Heijboer AC, Van Moorselaar J et al: Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 2010;47:282.
20. Manda R, Kohno T, Matsuno Y et al: Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display. Genomics 1999;61:5.
21. Simon I, Liu Y, Krall KL et al: Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 2007;106:112.
22. Liao CH, Yeh SC, Huang YH et al: Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. Endocr Relat Cancer 2010;17:99.
23. He YW, Li H, Zhang J, Hsu CL et al: The extracellular matrix protein mindin is a patternrecognition molecule for microbial pathogens. Nat Immuno 2004;5:88.
24. Jia W, Li H and He YW: The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. Blood 2005;106:3854.
25. Kim KA, Wagle M, Tran K et al: R-spondin family members regulate the Wnt pathway by a common mechanism. Mol Biol Cell 2008;19:2588.
26. Parry R, Schneider D, Hudson D et al: Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res 2005;65:8397.
27. Romanuik TL, Ueda T, Le N et al: Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol 2009;175:2264.
28. Sardana G, Jung K, Stephan C et al: Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008;7:3329.
29. Kim JW, Kim ST, Turner AR et al: Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 2012;7:e48455.
30. Lexander H, Palmberg C, Hellman U et al: Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics 2006;6:4370.
31. Aihara M, Lebovitz RM, Wheeler TM et al: Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol 1994;151:1558.